Teriparatide biosimilar (Dongguan Baolijian Bioengineer)
重组人甲状旁腺激素（1-34）（东莞宝丽健生物工程）
Report date: 2022/03/21 20:00:32
Base Information
Drug NameTeriparatide biosimilar (Dongguan Baolijian Bioengineer)
Drug Alias Name
Classification
Mechanisms of Action
Targets
Therapy Area/Indications
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/Territory
CombinationsNo
Global Highest StatusPending (Phase 3 Clinical)
Highest Status in ChinaPending
Originator CompaniesDongguan Baolijian Bioengineering Research And Development Co Ltd
China Registration ClassN/A
Develop Information
Active CompaniesN/A
Inactive CompaniesDongguan Baolijian Bioengineering Research And Development Co Ltd
Active IndicationsN/A
Inactive Indications
Other Information
ATC Code
Related LinksN/A